??????????? ??????????? ????????????????????????????????????????????????????????????Negotiations above the 2022 reauthorization propose that market priorities involve greater software of authentic-entire world proof, regulatory certainty, and amplified interaction in between FDA and business in the drug software approach.???????????????????????????